Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enlivex Therapeutics Ltd ENLV

Healthcare Biotechnology
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages... see more

Recent & Breaking News (NDAQ:ENLV)

Bio Blast Pharma Announces Initiation of Its Canadian OPMD Clinical Study Center at McGill University, Montreal

GlobeNewswire September 22, 2014

BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study in OPMD

GlobeNewswire September 17, 2014

Bio Blast Pharma Ltd. (NASDAQ: ORPN) to Ring The NASDAQ Stock Market Opening Bell

GlobeNewswire September 8, 2014

BioBlast to Ring the NASDAQ Stock Market Opening Bell

GlobeNewswire September 8, 2014

BioBlast Pharma Reports Second Quarter Financial Results

GlobeNewswire August 29, 2014

BioBlast Receives Notice of Allowance From USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich's Ataxia

GlobeNewswire August 18, 2014

Bio Blast Pharma Prices Initial Public Offering of $35,200,000 of Ordinary Shares

GlobeNewswire July 30, 2014